Catalog No.
Product Name
Application
Product Information
Citations
-
Pheromone Inhibitor
(Z)-7-Dodecen-1-ol is a pheromone inhibitor that primarily targets the signaling pathways of pheromone receptors. This compound effectively inhibits the activity of the attractant Z-7-dodecen-1-yl acetate, thereby interfering with pheromone-mediated behaviors. It is widely utilized in research applications focused on entomology and chemical ecology, particularly in studies examining insect communication and mating disruption. -
Endogenous Metabolite
Eicosapentaenoyl chloride is a derivative of eicosapentaenoic acid that serves as a fatty acyl chloride. This compound is utilized in the synthesis of fatty acid conjugates to improve the lipophilicity and cellular permeability of various bioactive molecules, including (–)-epigallocatechin gallate and salicylic acid. Its application is significant in enhancing the bioavailability and effectiveness of therapeutic agents in chemical research. -
Endogenous Metabolite
(Z)-Methyl heptadec-10-enoate is an ester derived from cis-10-heptadecenoic acid and functions as an endogenous metabolite. This compound exhibits key biological activities related to fatty acid metabolism and is often utilized in studies involving biodiesel components. Its specific structure and properties make it valuable for research applications in lipid biochemistry and metabolic profiling. -
Endogenous Metabolite
N-Methylarachidonamide is an analog of the endogenous cannabinoid anandamide, primarily targeting the central cannabinoid receptor (CB1). This compound exhibits a binding affinity with a Ki value of 60 nM for CB1, influencing various physiological processes. Additionally, it effectively inhibits rat glial gap junction cell-cell communication by 100% at a concentration of 50 μM. As such, N-Methylarachidonamide is a valuable tool for research exploring cannabinoid receptor signaling and its implications in neurobiology and related fields. -
Endogenous Metabolite
DU717 is an antihypertensive agent that targets endogenous metabolites to modulate blood pressure regulation. It is utilized in research focused on cardiovascular health and the physiological pathways involving blood pressure homeostasis. Its biological activity may provide insights into treatments for hypertension and related cardiovascular disorders. -
Endogenous Metabolite
Tuftsin diacetate is a tetrapeptide that acts as a potent activator of macrophages and microglia. It enhances immune responses and plays a critical role in modulating inflammation. This compound is valuable for research applications focused on innate immunity, neuroinflammation, and the study of macrophage biology. -
sEH/FXR Ligand
sEH/FXR-IN-1 is a selective ligand for soluble epoxide hydrolase (sEH) and the farnesoid X receptor (FXR). This compound demonstrates biological activity by modulating sEH enzymatic activity and influencing FXR signaling pathways. It is utilized in research related to metabolic disorders, inflammation, and liver disease, offering potential insights into therapeutic strategies targeting these pathways. -
FAAH/sEH Inhibitor
Dual FAAH/sEH-IN-1 is a potent dual inhibitor of soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH), exhibiting IC50 values of 9.6 nM and 7 nM, respectively. This compound demonstrates significant antinociceptive effects during the inflammatory phase, making it a valuable tool for studying pain pathways and potential therapeutic interventions in pain management. Its ability to modulate lipid signaling pathways positions it for applications in neurobiology and pharmacology research. -
FAAH Inhibitor
ST4070 is a potent and selective reversible inhibitor of fatty acid amide hydrolase (FAAH). This compound elevates endocannabinoid levels in the brain, effectively counteracting neuropathic pain in preclinical animal models. Furthermore, ST4070 modulates endocannabinoid tone in brain regions associated with emotional regulation and produces significant anxiolytic-like effects in rodents. It is a valuable tool for research into neuropathic pain and anxiety disorders. -
FAAH Inhibitor
URB524 is an irreversible inhibitor of fatty acid amide hydrolase (FAAH) through the aminoformylation of Ser241. This compound demonstrates significant analgesic, antidepressant, and anxiolytic properties, making it valuable for research in pain management, mood disorders, and anxiety studies. Its ability to modulate endocannabinoid levels positions URB524 as a crucial tool in the investigation of cannabinoid-related pathways and therapeutics. -
FAAH Inhibitor
URB937 is a potent and peripherally restricted inhibitor of fatty acid amide hydrolase (FAAH), with an IC50 value of 26.8 nM. This compound effectively elevates anandamide levels, making it valuable for studies on endocannabinoid signaling. Due to its inability to cross the blood-brain barrier, URB937 is particularly useful for investigating peripheral FAAH activity and its implications in various biological processes and therapeutic applications. -
FAAH Inihibitor
Oleoyl ethyl amide is a selective fatty acid amide hydrolase (FAAH) inhibitor. This compound demonstrates potential in modulating bladder overactivity through its ability to enhance the endocannabinoid signaling pathway. Research applications include studies focused on urinary disorders and the broader investigation of endocannabinoid system effects on bladder function. -
FAAH Inhibitor
TC-F2 is a reversible non-covalent inhibitor of fatty acid amide hydrolase (FAAH), exhibiting an IC50 of 28 nM. By modulating FAAH activity, TC-F2 is pertinent for research focused on various human diseases, including cancer, pain, inflammation, as well as neurological, metabolic, and cardiovascular disorders. This compound provides a valuable tool for investigating the therapeutic potential of FAAH inhibition in these areas. -
FAAH Effective Substrate
Sob-AM2 is a high-affinity substrate for fatty acid amide hydrolase (FAAH), exhibiting a Km of 1.3 μM and demonstrating effective blood-brain barrier permeability. This compound facilitates elevated delivery of Sobetirome to the central nervous system while minimizing peripheral exposure, thus activating central thyroid hormone receptor β (TRβ). Additionally, Sob-AM2 has been shown to protect against myelin and axon degeneration in models of experimental autoimmune encephalomyelitis (EAE), making it a valuable tool for investigating neuroprotective mechanisms and central nervous system disorders. -
FAAH/MAGL Inhibitor
FAAH/MAGL-IN-5 is a potent inhibitor of both fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), exhibiting equipotent inhibitory activity with an IC50 of 1.2 nM. This dual inhibition results in enhanced endocannabinoid levels, contributing to neuroprotective effects. FAAH/MAGL-IN-5 is valuable in research applications focused on pain management, neurodegenerative disorders, and the modulation of the endocannabinoid system. -
FAAH/MAG Inhibitor
AKU-005 is a dual inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), exhibiting IC50 values of 63 nM and 389 nM for rat and human FAAH, respectively. This compound demonstrates significant potential in the study of trigeminal hyperalgesia and related pain pathways, making it a valuable tool for researchers investigating endocannabinoid signaling and pain modulation mechanisms. -
FAAH Inhibitor
AM 374 is a potent inhibitor of fatty acid amide hydrolase (FAAH), demonstrating an IC50 value of 13 nM for amidase activity inhibition. This compound is utilized in research focused on neurological diseases, contributing to the understanding of endocannabinoid signaling pathways and their therapeutic potential in various conditions. -
FAAH/MGL Inhibitor
FAAH/MAGL-IN-4 is a selective inhibitor of fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL), exhibiting IC50 values of 9.1 nM and 7.9 μM, respectively. This compound plays a critical role in modulating endocannabinoid signaling pathways, making it valuable for investigating pain mechanisms and central nervous system disorders. Its potent inhibitory activity supports research in neurology and pain management applications. -
FAAH/MAGL Inhibitor
Irafamdastat is a potent inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), exhibiting IC50 values of ≤ 100 nM for human FAAH and 100 nM-1 µM for human MAGL. This compound has demonstrated antiepileptic effects and is valuable for research into pain management, neuroprotection, and anxiety. Its dual inhibition of FAAH and MAGL positions it as a significant tool for exploring endocannabinoid system modulation in various therapeutic contexts. -
FAAH Inhibitor
FAAH-IN-6 is a potent fatty acid amide hydrolase (FAAH) inhibitor that effectively crosses the blood-brain barrier, exhibiting IC50 values of 0.72 nM and 0.28 nM for human and rat FAAH, respectively. This compound demonstrates significant dose-dependent analgesic effects in preclinical models of neuropathic and inflammatory pain, making it valuable for research on pain management and therapeutic interventions targeting the endocannabinoid system. -
FAAH Substrate
N-Nervonoyl taurine, a fatty acid-taurine conjugate derived from nervonic acid, serves as a substrate for fatty acid amide hydrolase (FAAH). This compound plays a significant role in lipid metabolism and inflammation regulation. It is used in research applications focused on understanding FAAH's enzymatic activity and its implications in various physiological and pathological processes. -
FAAH Inhibitor
N-(3-Methoxybenzyl)Palmitamide is an inhibitor of fatty acid amide hydrolase (FAAH), which is crucial in the regulation of endocannabinoid signaling. This compound exhibits significant anti-inflammatory and analgesic properties, making it a valuable tool for research into pain relief and the treatment of central nervous system degenerative disorders. Its potential applications extend to studying the therapeutic effects of endocannabinoids in various biological contexts. -
FAAH Inhibitor
JNJ-40355003 is a potent and selective fatty acid amide hydrolase (FAAH) inhibitor. It effectively enhances the levels of endocannabinoids, contributing to its biological activity in the modulation of pain, anxiety, and inflammation. This compound is valuable for research in cannabinoid signaling and therapeutic applications targeting the endocannabinoid system. -
FAAH Inhibitor
JP83 is an irreversible inhibitor of fatty acyl amide hydrolase (FAAH), demonstrating an IC50 of 1.6 nM in competitive activity-based protein profiling (ABPP) assays. This compound is valuable for studying the role of FAAH in regulating endocannabinoid signaling and its implications in pain modulation and various neurological disorders. Researchers utilize JP83 to elucidate the mechanistic pathways of FAAH inhibition and explore potential therapeutic applications in cannabinoid pharmacology. -
FAAH Inhibitor
SSR411298 is a selective and reversible inhibitor of fatty acid amide hydrolase (FAAH). This compound demonstrates significant potential in modulating endocannabinoid levels, making it a valuable tool for research related to post-traumatic stress disorder (PTSD) and other neuropsychiatric conditions. Its oral bioavailability further enhances its utility in various preclinical studies. -
FAAH Inhibitor
JP104 is an irreversible inhibitor of fatty acid amide hydrolase (FAAH), exhibiting a potent pIC50 of approximately 8. This compound effectively modulates endocannabinoid levels, making it a valuable tool for studying pain management, neurobiology, and potential therapeutic applications in anxiety and stress-related disorders. Its mechanism of action provides unique insights into the biological pathways influenced by FAAH inhibition. -
FAAH Inhibitor
ASP 8477 is a selective inhibitor of fatty acid amide hydrolase (FAAH), demonstrating IC50 values of 3.99 nM for human FAAH-1, 1.65 nM for the FAAH-1 (P129T) variant, and 57.3 nM for FAAH-2. This compound exhibits central nervous system activity, making it valuable in analgesia research. Its potent inhibition of FAAH positions ASP 8477 as a significant tool for studying pain modulation and endocannabinoid signaling pathways. -
FAAH Inhibitor
PF-622 is a selective inhibitor of fatty acid amide hydrolase (FAAH), which plays a crucial role in the endocannabinoid system. This compound is utilized in research focused on analgesic, anxiolytic, and antidepressant effects, making it valuable for studies exploring pain management and mood disorders. Its ability to modulate endocannabinoid levels enables investigation into therapeutic strategies for various neurological conditions. -
FAAH/MAGL Inhibitor
FAAH/MAGL-IN-3 is an irreversible inhibitor targeting fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) with IC50 values of 179 nM and 759 nM, respectively. This dual inhibitor is valuable for studying endocannabinoid metabolism and its implications in various physiological and pathological processes. Notably, FAAH/MAGL-IN-3 demonstrates low permeability in the PAMPA assay, indicating a potential for selective activity in research applications. -
FAAH Inhibitor
3-Decyl-5,5'-diphenyl-2-thioxo-4-imidazolidinone is a potent inhibitor of fatty acid amide hydrolase (FAAH) with a pI50 of 5.89. This compound exhibits significant activity against endocannabinoids and lipid mediators, making it relevant for studies in pain management, inflammation, and cannabinoid signaling pathways. Its limited affinity for cannabinoid receptors CB(1) and CB(2) allows for targeted research into FAAH-related physiological processes without direct receptor modulation. -
FAAH/cPLA2α Inhibitor
FAAH/cPLA2α-IN-1 is a dual inhibitor targeting fatty acid amide hydrolase (FAAH) and cytosolic phospholipase A2 alpha (cPLA2α), exhibiting IC50 values of 32 nM and 47 nM, respectively. This compound demonstrates potential anti-inflammatory properties by modulating lipid signaling pathways, making it valuable for research into pain management, neuroprotection, and inflammatory responses. Its use in various preclinical studies may provide insights into the therapeutic potential of FAAH and cPLA2α inhibition. -
FAAH
MM-433593 is a selective inhibitor of fatty acid amide hydrolase-1 (FAAH-1), targeting the endocannabinoid system to modulate pain and inflammation pathways. It demonstrates effective pharmacokinetic properties, including a biphasic elimination profile characterized by a rapid distribution and a slower elimination phase. With moderate oral bioavailability (14-21%), MM-433593 undergoes metabolism primarily through the oxidation of its indole ring's methyl group, yielding various sulfate, glucuronide, and glutathione-conjugated metabolites, making it a valuable tool for investigating FAAH-related biological processes and therapeutic applications. -
FAAH Inhibitor
SA57 is a selective inhibitor of fatty acid amide hydrolase (FAAH), exhibiting IC50 values of 3.2 nM and 1.9 nM for mouse and human FAAH, respectively. In addition to its primary target, SA57 demonstrates inhibitory effects on 2-arachidonoylglycerol hydrolases, including monoacylglycerol lipase (MAGL) with IC50s of 410 nM and 1.4 μM for mouse and human, as well as mouse α/β-hydrolase domain-containing protein 6 (mABHD6) with an IC50 of 850 nM. This compound is valuable for research related to the endocannabinoid system and pain management studies. -
FAAH/MAGL Inhibitor
FAAH/MAGL-IN-2 is a potent, reversible inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). It exhibits IC50 values of 11 nM and 36 nM for FAAH and MAGL, respectively, demonstrating significant inhibitory potency. This compound effectively crosses the blood-brain barrier, making it a valuable tool for investigating the role of endogenous lipids in neuropathic pain while minimizing locomotion impairment. Its selective inhibition profile facilitates research into therapeutic approaches for pain management and related disorders. -
FAAH Inhibitor
FAAH-IN-7 is a potent and reversible inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 8.29 nM. This compound effectively reduces oxidative stress in 1321N1 astrocytes and demonstrates significant neuroprotective effects in ex vivo models of neuroinflammation. FAAH-IN-7 is valuable for studies involving neuroprotection and modulation of the endocannabinoid system in various neurological research applications. -
FAAH Inhibitor
URB532 is a selective inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 396 nM. This compound effectively elevates the levels of key endogenous lipid mediators, including arachidonic acid acetamide (AEA), palmitoylethanolamide (PEA), and oleamide (OEA) in the rat brain. URB532 has demonstrated notable anxiolytic and analgesic effects, making it a valuable tool for research on pain and anxiety modulation. -
FAAH Inhibitor
FAAH-IN-5 is an irreversible inhibitor of fatty acid amide hydrolase (FAAH) with a reported IC50 of 10.5 nM, demonstrating relative selectivity. This compound is suitable for research applications focused on endocannabinoid signaling pathways and pain modulation. Despite its potency, FAAH-IN-5 exhibits low permeability in the Parallel Artificial Membrane Permeability Assay (PAMPA), making it an important tool for studies in pharmacokinetics and bioavailability. -
FAAH Inhibitor
URB694 is a carbamate inhibitor of fatty acid amide hydrolase (FAAH) that irreversibly carbamoylates the catalytic serine residue in the FAAH active site. This compound exhibits notable antidepressant-like effects and offers potential cardioprotective properties. URB694 can also be utilized in the synthesis of 11C-Carbonyl-URB694, facilitating in vivo positron emission tomography (PET) imaging studies aimed at elucidating FAAH activity in the brain. -
AtFAAH Activator
MDPD is an activator of Arabidopsis fatty acid amide hydrolase (AtFAAH), promoting increased enzymatic activity of this important regulatory enzyme. This compound is utilized in research applications focused on lipid metabolism and amide hydrolysis pathways, contributing to the understanding of fatty acid signaling processes in plant biology. MDPD's ability to enhance AtFAAH activity makes it a valuable tool for studies investigating the physiological roles of fatty acid amides in Arabidopsis. -
FAAH Inhibitor
MK-4409 is a potent inhibitor of fatty acid amide hydrolase (FAAH) that demonstrates significant anti-inflammatory properties. It is primarily utilized in research focusing on inflammatory and neuropathic pain mechanisms. The compound’s ability to modulate endocannabinoid levels makes it a valuable tool for studying pain pathways and potential therapeutic interventions. -
FAAH Inhibitor
OL-135 is a selective and reversible inhibitor of fatty acid amide hydrolase (FAAH) that effectively penetrates the central nervous system. It demonstrates notable analgesic properties, making it a valuable tool for research into pain modulation and the endocannabinoid system. This compound is suitable for studies exploring the therapeutic potential of FAAH inhibition in various neurological disorders. -
FAAH Inhibitor
FAAH-IN-8 is a competitive inhibitor of fatty acid amide hydrolase (FAAH), exhibiting an IC50 value of 6.7 nM and a Ki value of 5 nM. This compound demonstrates high blood-brain barrier permeability and possesses a notable antioxidant profile without neurotoxic effects. FAAH-IN-8 is valuable for research applications involving pain management, neuroinflammation, and cannabinoid modulation. -
FAAH Inhibitor
VDM11 is a potent and selective inhibitor of fatty acid amide hydrolase (FAAH), serving as a key modulator in endocannabinoid signaling. By inhibiting FAAH, VDM11 enhances the levels of anandamide, which can contribute to various physiological effects, including pain modulation and neuroprotection. This compound is beneficial for research applications examining endocannabinoid pathways and developing therapeutics for related disorders. -
FAAH Inhibitor
JNJ-40413269 is a potent inhibitor of fatty acid amide hydrolase (FAAH), demonstrating inhibition of human and rat FAAH with IC50 values of 28 nM and 270 nM, respectively. This compound exhibits notable analgesic efficacy in the rat spinal nerve ligation model, making it a valuable tool for pain research. Additionally, JNJ-40413269 showcases favorable pharmacokinetic properties in rats, supporting its potential utility in pharmaceutical development. -
FAAH Substrate
Arachidonamide is a substrate for fatty acid amide hydrolase (FAAH), an important enzyme in the endocannabinoid system. This compound is utilized in research to investigate the biochemical pathways involving anandamide metabolism and its implications in various physiological processes. Arachidonamide can serve as a valuable tool in studies focused on pain relief, neuroprotection, and inflammation. -
FAAH Inhibitor
FAAH-IN-9 is an irreversible inhibitor of fatty acid amide hydrolase (FAAH) with a Ki value of 0.02 nM. This compound is specifically designed to enhance endocannabinoid signaling by preventing the degradation of endogenous fatty acid amides. FAAH-IN-9 is valuable for research into pain management, neuroprotection, and other physiological processes influenced by endocannabinoids. -
FAAH Substrate
Arachidonoyl m-nitroaniline is a substrate for fatty acid amide hydrolase (FAAH), facilitating the measurement of FAAH activity in biochemical assays. This compound serves as a reliable tool for researchers investigating the metabolism of fatty acid amides and the role of FAAH in various biological processes. Its utilization aids in elucidating the enzymatic mechanisms and potential therapeutic targets related to endocannabinoid signaling and pain modulation. -
FAAH Inhibitor
MK-3168 (12C) is a potent FAAH inhibitor exhibiting IC50 values of 1.0 nM for human, 5.5 nM for rhesus, and 1.7 nM for rat models. This compound demonstrates significant brain uptake and produces a FAAH-specific signal, making it a valuable tool in neurobiological research. MK-3168 (12C) is also applicable as a PET tracer for studying FAAH activity in vivo, facilitating insights into cannabinoid signaling pathways. -
FAAH Inhibitor
CAY10435 is a β-ketooxazapyridine that selectively inhibits fatty acid amide hydrolase (FAAH). Demonstrating antimicrobial activity, CAY10435 binds non-competitively to FAAH in Dictyostelium discoideum with a dissociation constant (Kd) of 0.57 nM. This compound is valuable for studying FAAH-related pathways and exploring potential therapeutic applications targeting lipid signaling. -
FAAH Inhibitor
JNJ-42165279 dihydrochloride is a selective inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 70 nM for human FAAH and 313 nM for rat FAAH. This compound enhances endocannabinoid levels by preventing the breakdown of fatty acid amides, which can lead to increased pain relief and anti-inflammatory effects. JNJ-42165279 is utilized in research applications focusing on pain management, neuroprotection, and the modulation of the endocannabinoid system.
